1190 / 1708
SJCRH study (Lucas )
•
Prognostic relevance of Curie score with advances in systemic therapy requires
•
re-evaluation
•
•
Early
metastatic site failure is usually at a
new
site while
prior/old
MSF
usually occurs
later
•
•
Inability to complete systemic therapy & presence of lung metastases
are risk factors for progression at
new metastatic sites
•
•
Persistent MIBG avid disease is insufficiently controlled
with adjuvant
doses
•
(21.6-23.4 Gy)
•
•
MIBG avidity is a reasonable way to select high risk sites
for recurrence